Compare STNE & VERA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | STNE | VERA |
|---|---|---|
| Founded | 2012 | 2016 |
| Country | Cayman Islands | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.3B | 3.2B |
| IPO Year | 2018 | 2021 |
| Metric | STNE | VERA |
|---|---|---|
| Price | $10.84 | $35.78 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 8 | 10 |
| Target Price | $19.19 | ★ $81.30 |
| AVG Volume (30 Days) | ★ 4.8M | 1.2M |
| Earning Date | 05-14-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $15.07 | N/A |
| Revenue Next Year | $6.05 | $472.48 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $11.58 | $18.76 |
| 52 Week High | $19.95 | $56.05 |
| Indicator | STNE | VERA |
|---|---|---|
| Relative Strength Index (RSI) | 25.33 | 32.36 |
| Support Level | N/A | $20.11 |
| Resistance Level | $15.80 | $42.77 |
| Average True Range (ATR) | 0.64 | 2.30 |
| MACD | -0.40 | -0.67 |
| Stochastic Oscillator | 0.70 | 1.06 |
StoneCo Ltd is a provider of financial technology solutions. It serves MSMBs solutions, at fair prices, and provides the customer experience to help them manage their businesses and sell more. Its Stone Business Model combines end-to-end, cloud-based technology platforms; differentiated hyper-local and integrated distribution approaches; and white-glove, on-demand customer service. It has two segments Financial Services segment, which includes payments solutions, digital banking, credit, insurance solutions as well as the registry business. In the Software segment solution includes POS/ERP, TEF and QR Code gateways, reconciliation, CRM, OMS, e-commerce platform, engagement tool, ads solution, and marketplace hub. It generates the majority of its revenue from the Financial Services segment.
Vera Therapeutics Inc is a clinical stage biotechnology company. It is focused on developing and commercializing transformative treatments for patients with serious immunological diseases. The company's product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection once weekly that blocks both B lymphocyte stimulator and a proliferation-inducing ligand, which stimulate B cells and plasma cells to produce autoantibodies contributing to certain autoimmune diseases.